Eli Lilly secures Retatrutide exclusivity

Eli Lilly has not announced a new exclusivity award for retatrutide, but the company and the U.S. Food and Drug Administration already say the investigational obesity and diabetes drug cannot be lawfully compounded. Lilly’s medical information site says retatrutide is not available in the consumer market and that Lilly is “the only lawful proprietor” of the molecule. The FDA says retatrutide cannot be used in compounding under federal law. Those statements, rather than a fresh regulatory grant, appear to be the factual basis for social-media claims that Lilly has “secured exclusivity” over the peptide. ### Did Lilly just win a new exclusivity right for retatrutide? No public FDA source reviewed for this article shows a new market-exclusivity award for retatrutide as of May 16, 2026. Retatrutide does not appear in the FDA’s Orange Book, which tracks approved drugs and their patent and exclusivity information, because the molecule is still investigational and has not been approved for sale. (medical.lilly.com) Lilly’s own description is narrower and more direct. The company says retatrutide is “an investigational molecule,” that it is supplying it only to participants in Lilly-sponsored clinical trials, and that it is not available in the consumer market. ### Why are people saying retatrutide is off-limits outside Lilly? The FDA says retatrutide “cannot be used in compounding under federal law.” The agency groups retatrutide with cagrilintide as substances that cannot legally be compounded, even as it discusses broader concerns about unapproved GLP-1 drugs sold for weight loss. (fda.gov) (medical.lilly.com) Lilly goes further in its medical information page, stating that “Lilly is the only lawful proprietor of retatrutide.” That language supports the claim that third parties cannot legally market compounded retatrutide, but it is not the same thing as a newly disclosed FDA exclusivity period for an approved drug. ### What has the FDA said about the wider peptide and GLP-1 market? (fda.gov) On February 6, 2026, FDA Commissioner Martin Makary said the agency would take “decisive steps” to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs. The statement named Hims & Hers and other compounding pharmacies as examples of companies mass-marketing products as similar alternatives to approved drugs. (medical.lilly.com) The FDA also says unapproved GLP-1 versions do not undergo agency review for safety, effectiveness or quality before marketing. In a separate safety page, the agency said it had established an import alert to help stop GLP-1 active ingredients with potential quality concerns from entering the U.S. supply chain. (fda.gov) ### Is retatrutide even on the market yet? Retatrutide is still in Phase 3 testing. Lilly reported positive topline Phase 3 obesity data in December 2025 and positive topline Phase 3 type 2 diabetes data on March 19, 2026. The company described the drug in both releases as an investigational once-weekly triple hormone receptor agonist targeting GIP, GLP-1 and glucagon. (fda.gov) In the obesity study, Lilly said patients on the 12 mg dose lost an average of 28.7% of body weight at 68 weeks. In the diabetes study, Lilly said patients on the 12 mg dose lost an average of 36.6 pounds, or 16.8%, at 40 weeks. ### Where do the affordability arguments come from? Zepbound, Lilly’s approved obesity drug based on tirzepatide rather than retatrutide, is one benchmark critics use when they compare branded medicines with grey-market peptides. (investor.lilly.com) Lilly said in February 2026 that Zepbound patients could access all doses in vial or KwikPen form at self-pay prices “starting at $299” a month through LillyDirect, and the company said in March that the KwikPen self-pay option would also be available at major pharmacies nationwide starting at $299 per month for the 2.5 mg dose. Those official prices are far below older list-price comparisons often cited online, but they apply to an approved Lilly product, not to retatrutide, which is not commercially available. The next concrete milestone for retatrutide is clinical: Lilly said on December 11, 2025 that seven additional Phase 3 trial readouts were expected in 2026. (investor.lilly.com 1) (investor.lilly.com 2)